Clinical Trial Update: A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

This is an update on a Phase 1/2 clinical trial evaluating the combination of amivantamab and capmatinib for unresectable metastatic non-small cell lung cancer;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• Tabrecta (Capmatinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING